

ASX ANNOUNCEMENT

27 January 2026

Quarterly Activities & Appendix 4C December 2025

- **Financial Highlights**

- Q2 EBITDA¹ of ~\$1.0m
- 1H26 EBITDA¹ of ~\$1.48m
- Eighth consecutive quarter of positive EBITDA¹
- Quarterly sales revenue of \$6.5m, up 41% vs PCP
- Rolling 12-month sales revenue of ~\$22m
- Gross margin maintained above 61%
- Cash receipts of \$6.2m, up 43% vs PCP

- **Cash Position**

- Net operating cash inflow of ~\$1.24m (including R&D rebate)
- Biome repaid \$722k into its working capital facilities
- Cash balance increased by \$421k to \$3.36m at 31 December 2025

Microbiome health company Biome Australia Limited (ASX: BIO) (*Biome or the company*) is pleased to provide its Appendix 4C and Activity Report for the quarter ended 31 December 2025.

Biome has delivered its best quarterly result to date with sales revenue of \$6.5m. This result represents growth of 41% on the prior corresponding period. The company has now achieved rolling 12-month sales revenue of ~\$22m.

Biome has also delivered EBITDA¹ of ~\$1.0m in Q2, representing the company's eighth consecutive quarter of positive EBITDA¹, and taking 1H26 EBITDA¹ to ~\$1.48m.


¹ EBITDA as measured, excl Share Based Payments

Customer receipts were \$6.2m, up 43% on the prior corresponding period. Combined with the FY25 R&D rebate of \$657k received in the quarter, Biome generated net operating cash inflow of ~\$1.24m.

The company repaid \$722k into its working capital facilities during the quarter, reflecting strong cash generation. After accounting for lease payments (\$29k), investing activities (\$112k), and a \$47k receipt from the extinguishment of an employee loan, cash at 31 December 2025 increased by \$421k to \$3.36m.

Biome maintained its gross margin above 61% for Q2 FY26.

Quarterly Sales Revenue with Rolling 12 months sales




Biome Australia Managing Director and Founder Blair Vega Norfolk said:

"Q2 represents Biome's strongest quarterly financial result to date, with EBITDA of ~\$1.0m and record sales revenue of \$6.5m. This result reflects the continued execution of our growth strategy across both domestic and international markets.

With rolling 12-month revenue now at ~\$22m, gross margins consistently above 61%, and eight consecutive quarters of positive EBITDA, the business has established a scalable platform. As revenue continues to grow, we expect an increasing proportion to flow through to earnings and cash generation.

Strong cash flow in the quarter allowed us to repay \$722k into our working capital facilities while still growing our cash balance, a clear demonstration of the financial discipline underpinning our growth.

We remain focused on expanding our international footprint and strengthening our position as Australia's leading practitioner-only probiotic company."



Quarterly Financial Summary

Biome reported positive EBITDA¹ of ~\$1.0m for the Dec quarter (Q2FY26). Cash at the end of the quarter was \$3.36m. The company received \$47k in Q2 for the extinguishment of loans under the Company's Employee Loan Funded Share Plan. Cash inflows from operating activities for Q2 were ~\$1.24m.

Business activity expenses consist of sales, advertising and marketing costs of \$450k (a decrease of \$215k from previous quarter \$665k). Payments for inventory and fulfilment were ~\$2.79m. Other operating costs decreased by \$14k to \$29k, and research and development increased by \$4k to \$117k vs Q1. The balance of operating outflows were administration and staff costs totaling ~\$2.18m, an increase of \$283k from the previous quarter.

In Q2, the company received \$6.2m in cash receipts from customers, an increase of \$1.9m (vs PCP). At the end of Q2, the company held \$3.9m in inventory, an increase of \$500k from Q1 FY26. The total level of inventory as at 31 December 2025 has a wholesale value of \$10m.

The company notes that in Q2 Biome paid \$178,937 to directors of the company in fees, salaries and superannuation payments, as follows:

• Executive Director	\$120,000
• Non-executive Directors	\$58,937



Appendix 4C

Quarterly cash flow report for entities

subject to Listing Rule 4.7B

Name of entity

BIOME AUSTRALIA LIMITED (BIO)

ABN

51 627 364 014

Quarter ended ("current quarter")

DEC 2025

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (....6...months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	6,203	13,347
1.2	Payments for		
	(a) research and development	(117)	(230)
	(b) inventory & fulfilment	(2,788)	(6,272)
	(c) other operating costs	(29)	(72)
	(d) sales, advertising and marketing	(450)	(1,115)
	(e) staff costs	(1,770)	(3,379)
	(f) administration and corporate costs	(407)	(692)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(55)	(82)
1.6	Income taxes & FBT paid	(7)	(7)

1.7	Government grants including EMDG and R&D tax rebate incentives	657	657
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	1,237	2,155

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	(34)	(53)
	(d) investments in inventory		
	(e) intellectual property	(78)	(109)
	(f) other non-current assets (*leasehold improvements)		
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (**bank guarantee)		
2.6	Net cash from / (used in) investing activities	(112)	(162)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (from exercise of options)	47	108
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from issue of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings	–	–
3.6	Payments for lease liabilities	(29)	(58)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (repayments of borrowings)	(722)	(1,433)
3.10	Net cash from / (used in) financing activities	(704)	(1,383)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,935	2,746
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,237	2,155
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(112)	(162)

4.4	Net cash from / (used in) financing activities (item 3.10 above)	(704)	(1,383)
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	Cash and cash equivalents at end of period	3,356	3,356

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,356	2,935
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,356	2,935

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	179
6.2	Aggregate amount of payments to related parties and their associates included in item 2	nil

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount paid to Directors of the Company during the quarter was \$178,937 in fees, salaries and superannuation payments, as follows:

· Executive Director	\$120,000
· Non-executive Directors	\$58,937

7.	Financing facilities <i>Note: the term “facility” includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	5,000	1,500
7.2	Credit standby arrangements	Nil	n/a
7.3	Other (please specify)	Nil	n/a
7.4	Total financing facilities	5,000	1,500
7.5	Unused financing facilities available at quarter end		3,500
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

Biome Australia Trading Pty Ltd ("Biome Trading") a wholly owned subsidiary of The Company has entered into a \$5.0m secured debt facility ("Facility") with NAB for working capital purposes to fund future growth, comprising a \$3.5m NAB Invoice Finance Facility and a \$1.5m NAB Trade Finance Facility.

\$3.5m NAB Invoice Finance Facility

This facility will provide invoice funding for Biome's Australian accounts receivables. The current interest rate of the facility is 7.75%. The facility carries an application fee of \$12,250 plus a monthly facility fee of \$1,700. This is an ongoing facility with no set expiry date.

\$1.5m NAB Trade Refinance Facility

The current interest rate of the facility is 7.53% p.a. The facility carries an application fee of \$5,250 plus a facility fee of 1.3% p.a. This facility is set to expire on 27 February 2026, with the intention to have the term of the facility extended before expiry. The facility is secured by a General Security Agreement over the whole of Biome Trading's assets, a First ranking priority charge over the whole of Biome Trading's receivables (debtor) book and a Deed of Guarantee and Indemnity from the Company, supported by a General Security Agreement over the whole of the assets of the Company.

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	1,237
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,356
8.3	Unused finance facilities available at quarter end (item 7.5)	3,500
8.4	Total available funding (item 8.2 + item 8.3)	8,093
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

n/a

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

n/a

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

n/a

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 January 2026

Authorised by the Board

(Name of body or officer authorising release – see note 4)

Notes


1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub via [this link](https://investorhub.biomeaustralia.com/) (<https://investorhub.biomeaustralia.com/>).



About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics[®].

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients[®].

For more information visit: www.biomeaustralia.com

Investor Relations

corporate@biomeaustralia.com

(03) 9017 5800

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial



information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.

